Recent outbreaks such as Ebola and Zika alarmed vaccine experts, who worry that the scientific community isn’t prepared for emerging diseases. That concern has sparked new funding and collaboration—and along the way, experts say, vaccine science is advancing to speed up the fight against new pathogens.
Platform manufacturing, for example, can radically shorten the vaccine development timeline, National Institute for Allergy and Infectious Diseases scientists wrote in an article published in the Journal of the American Medical Association.
Newer approaches include DNA vaccines, mRNA vaccines, viral vectors, nanoparticles and virus-like particles, NIAID director Dr. Anthony Fauci told FiercePharma. Scientists can sequence a pathogen in a day or less and insert the genetic material into a vaccine platform “without ever having to grow the virus,” Fauci said.
In Zika, NIH scientists were able to enter human testing with a DNA vaccine just four months after sequencing the virus, cutting years off the development process. The government is testing its shot in phase 2 and could seek an emergency regulatory approval if another outbreak emerges, Dr. Fauci said.
Historically, preclinical testing took several years, according to the authors, followed by early clinical tests that take another few years. Efficacy testing and regulatory interactions could require another 10 years, they wrote, meaning it could take up to 20 years to develop a vaccine—and that’s if everything goes smoothly. Fauci said new technology could shrink the entire process to under five years.
Meanwhile, the Coalition for Epidemic Preparedness Innovations formed last year in response to the outbreaks and to better prepare for future outbreaks. The organization has raised hundreds of millions of dollars from the Gates Foundation and several governments.
This month, the coalition gave its first grant to Austria’s Themis to work on vaccines against Lassa fever and MERS. At the time, a CEPI spokesperson said “the fact that Themis has developed a versatile technology platform for the discovery, development and production of vaccine approaches is very attractive.”
“This means as well as focusing on MERS and Lassa we hope this technology will have value beyond those specific diseases,” she added.
By Eric Sagonowsky
Source: Fierce Pharma
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
